ARS Pharmaceuticals, Inc.SPRYNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P14
Within normal range
vs 2Y Ago
-3.2x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | -32.68% |
| 2024 | -3.38% |
| 2023 | 10.29% |
| 2022 | -9.36% |
| 2021 | 44.09% |
| 2020 | -34.57% |
| 2019 | 45.26% |
| 2018 | 0.00% |